Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Agmatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.41 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | F13A1 | P00488 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Agmatine SCHEMBL4535578 | 1.00 | ALOX15 (0.61) | ALOX15SMN1; SMN2CYP1A2MEN1KMT2A | |
| Sulfuric Acid SCHEMBL22440174 | 0.98 | ALOX15 (0.59) | ALOX15SMN1; SMN2CYP1A2MEN1KMT2A | |
| Agmatine SCHEMBL27686087 | 0.98 | ALOX15 (0.59) | ALOX15SMN1; SMN2CYP1A2MEN1KMT2A | |
| Agmatine SCHEMBL4727351 | 0.98 | ALOX15 (0.59) | ALOX15SMN1; SMN2CYP1A2MEN1KMT2A | |
| Sulfuric Acid SCHEMBL12803040 | 0.98 | ALOX15 (0.59) | ALOX15SMN1; SMN2CYP1A2MEN1KMT2A | |
| Agmatine SCHEMBL19647 | 0.91 | — | — | |
| Agmatine SCHEMBL5665180 | 0.91 | CYP1A2 (0.54) | ALOX15SMN1; SMN2CYP1A2MEN1KMT2A | |
| Agmatine SCHEMBL8579204 | 0.91 | CYP1A2 (0.54) | ALOX15SMN1; SMN2CYP1A2MEN1KMT2A | |
| Agmatine SCHEMBL30819275 | 0.91 | — | — | |
| Arcaine SCHEMBL1999196 | 0.91 | ALOX15 (0.70) | ALOX15SMN1; SMN2CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 862 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260115153-A1 | ANTI-ANXIETY COMPOSITION | RAVNAAS BRENT (US) | 2026-04-30 | — | — | US | claimed |
| US-12553134-B2 | Bendable nickel plating on flexible substrates | MACDERMID ENTHONE INC. (US) | 2026-02-17 | — | — | US | claimed |
| US-12497667-B2 | Quantitative detection method for six antibiotic drug resistant genes in aquatic product | ZHOUSHAN INSTITUTE FOR FOOD AND DRUG CONTROL (CN) | 2025-12-16 | — | — | US | claimed |
| US-20250367206-A1 | 1-METHYLXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | Ingenious Ingredients, LP (US) | 2025-12-04 | — | — | US | claimed |
| US-20250313801-A1 | SPECIFIC T CELL FOR PREVENTING OR TREATING CANCER, AND PREPARATION METHOD THEREOF | SUZHOU ERSHENG BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-10-09 | — | — | US | claimed |
| US-20250311762-A1 | FORMULATION AND METHOD FOR AN EXERCISE SUPPORTING NUTRITIONAL SUPPLEMENT | BullFit, LLC. (US) | 2025-10-09 | — | — | US | claimed |
| CN-120136508-A | High-fire-resistance concrete and preparation method thereof | 无锡瑞彻工程有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-119925625-A | Nucleic acid nanotube delivery material, preparation method and application thereof | 中国人民解放军陆军军医大学第二附属医院 | 2025-05-06 | — | — | CN | claimed |
| EP-4534652-A1 | SPECIFIC T CELL FOR PREVENTING OR TREATING CANCER, AND PREPARATION METHOD THEREFOR | Suzhou Ersheng Biopharmaceutical Co., Ltd. (CN) | 2025-04-09 | — | — | EP | claimed |
| CN-101717352-A | Method for synthesizing agmatine sulfate | UNIV ZHEJIANG TECHNOLOGY | 2010-06-02 | — | — | CN | claimed |
| US-20090269406-A1 | Therapeutic uses of biocompatible biogel compositions | PANITCH ALYSSA | 2009-10-29 | — | — | US | claimed |
| WO-2009123759-A2 | THERAPEUTIC USES OF BIOCOMPATIBLE BIOGEL COMPOSITIONS | MOERAE MATRIX, INC. (US) | 2009-10-08 | — | — | WO | claimed |
| CN-101121677-A | Agmatine sulfate dihydrate and medical use thereof | POISON MED INST PLA MED ACAD (CN) | 2008-02-13 | — | — | CN | claimed |
| US-7294743-B2 | Method for synthesis of acrylamide derivatives | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2007-11-13 | — | — | US | claimed |
| US-20070106090-A1 | Method for synthesis of acrylamide derivatives | CYTIVA SWEDEN AB (SE) | 2007-05-10 | — | — | US | claimed |
| EP-1675818-A1 | METHOD FOR SYNTHESIS OF ACRYLAMIDE DERIVATIVES | GE Healthcare Bio-Sciences AB (SE) | 2006-07-05 | — | — | EP | claimed |
| US-20060127337-A1 | Process for relaxing keratin fibres | L'OREAL (FR) | 2006-06-15 | — | — | US | claimed |
| WO-2005040092-A1 | METHOD FOR SYNTHESIS OF ACRYLAMIDE DERIVATIVES | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2005-05-06 | — | — | WO | claimed |
| US-20030152548-A1 | Synthesis and characterization of biodegradable cationic poly ( propylene fumarate-co-ethylene glycol) copolymer hydrogels modified with agmatine for enhanced cell adhesion | WILLIAM MARSH RICE UNIVERSITY | 2003-08-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313801-A1 | SPECIFIC T CELL FOR PREVENTING OR TREATING CANCER, AND PREPARATION METHOD THEREOF | CD4, CD69, CD47 | MAOA 3912/4885MAOB 4290/4885ALOX15 2485/4885 |
| US-20260115153-A1 | ANTI-ANXIETY COMPOSITION | SLC7A11, SLC6A12, SLC6A6 | MAOA 2912/4885MAOB 3103/4885ALOX15 4812/4885 |
| US-12553134-B2 | Bendable nickel plating on flexible substrates | NUDT1, GDA, GMPS | MAOA 230/4885MAOB 192/4885ALOX15 4605/4885 |
| US-20060127337-A1 | Process for relaxing keratin fibres | KRT18, TPM4, MYLK | MAOA 3643/4885MAOB 4253/4885ALOX15 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.